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Abstract Inflammatory activity in atherosclerotic plaque is
a risk factor for plaque rupture and atherothrombosis and
may direct interventional therapy. Inflammatory activity can
be evaluated at the (sub)cellular level using in vivo
molecular MRI. This paper reviews recent progress in
contrast-enhanced molecular MRI to visualize atheroscle-
rotic plaque inflammation. Various MRI contrast agents,
among others ultra-small particles of iron oxide, low-
molecular-weight Gd-chelates, micelles, liposomes, and
perfluorocarbon emulsions, have been used for in vivo
visualization of various inflammation-related targets, such
as macrophages, oxidized LDL, endothelial cell expression,
plaque neovasculature, MMPs, apoptosis, and activated
platelets/thrombus. An enzyme-activatable magnetic reso-
nance contrast agent has been developed to study myelo-
peroxidase activity in inflamed plaques. Agents creating
contrast based on the chemical exchange saturation transfer
mechanism were used for thrombus imaging. Transfer of
these molecular MRI techniques to the clinic will critically
depend on the safety profiles of these newly developed
magnetic resonance contrast agents.
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Introduction
Atherothrombotic diseases contribute to a major portion of
mortality in the Western world. Inflammatory activity in the
atherosclerotic plaque is a key player in the progress of
atherosclerosis and the risk for plaque rupture [1]. Sensitive
and specific imaging biomarkers are highly desired for
prognostication of atherosclerosis in the high-risk popula-
tion. Local plaque imaging biomarkers, which can direct
interventional cardiologists and vascular surgeons to dis-
eased sites, are therefore of great interest. At present,
serologic markers do not accomplish this need sufficiently.
Inflammatory activity can be evaluated at the cellular
(macrophages, neutrophils, and lymphocytes) or subcellular
(secreted and intracellular enzymes, membrane-bound pro-
teins) level. Various noninvasive imaging techniques are
available for evaluation of the levels of these inflammation-
related cells, proteins, or enzymes. PET, SPECT, CT,
ultrasound, and MRI are all clinically available imaging
modalities that could play a role in molecular imaging of
plaque inflammation [2]. MRI has the distinct advantage that
it is safe, does not involve ionizing radiation, has a high
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penetration depth, and is capable of providing molecular
information with high spatial resolution in an anatomical and
physiological context.
During the process of atherogenesis, inflammation
aggravates endothelial dysfunction and vice versa. Various
more or less sequential processes take place during the
development from a fatty streak to a rupture-prone or
ruptured plaque [1]. First, low-density lipoprotein (LDL)
uptake into the sub-intima is followed by oxidation of LDL
by tyrosyl radicals and aldehydes, which result from
myeloperoxidase produced by plaque neutrophils and
macrophages. Oxidized LDL (ox-LDL) stimulates endothe-
lial cell dysfunction, leading to inflammatory cell migration
and activation. Recruited macrophages release matrix-
degrading enzymes and other factors that eventually result
in apoptosis of smooth muscle cells, endothelial cells, and
macrophages. Eventually, these processes may lead to
fibrous cap thinning, lipid core growth, formation of fragile
intra-plaque neovasculature, intra-plaque hemorrhage, and
finally fibrous cap rupture. Subsequent formation of a
thrombus may cause an acute thrombotic event.
Why some atherosclerotic plaques remain stable and
why certain plaques develop into rupture-prone plaques at a
fast pace, is currently unknown and therefore the subject of
intense research. It is hypothesized that the inflammatory
status of the plaque plays an important role in the
development of so-called unstable plaque. In this review,
we will therefore focus on recent progress in molecular
MRI using contrast agents to noninvasively visualize
atherosclerotic plaque inflammation. In the following
sections we will discuss a number of targets, according to
the sequence of atherosclerotic processes (ox-LDL, endo-
thelial cells, neovascularization, macrophages, apoptotic
cells, activated platelets, thrombus), that have been used to
image various aspects of the inflammatory pathways in
atherosclerosis.
Ox-LDL
Targeting specific epitopes of ox-LDL in atherosclerotic
plaque has successfully been demonstrated using
antibody-conjugated paramagnetic micelles. Application
of ox-LDL–targeted micelles in apoE–/– mice resulted
in a specific MRI signal enhancement of plaques in the
aortic wall at 72 and 96 h after intravenous injection in
comparison to the use of control non-conjugated
micelles and nonspecific IgG-conjugated micelles [3].
Despite this success, clinical application of targeted
micelles may be limited due to the observed long blood
circulation times (>14 h) and high liver uptake (20% of
the injected dose). Although the use of gadolinium (Gd) is
generally believed to be safe, excessive retention of Gd-
chelates in organs needs to be avoided, as Gd toxicity was
recently implicated in the occurrence of cell apoptosis [4,
5] and nephrogenic systemic fibrosis (NSF) in patients
with renal dysfunction [6].
Briley-Saebo and coworkers [7] also developed a lipid-
coated ultra-small superparamagnetic iron particles (LUS-
PIOs) (<20 nm) targeted to oxidation-specific epitopes on
ox-LDL in the plaque of apoE–/– mice. Upon in vivo
application in apoE–/– mice, enhancement of the aortic wall
was observed in gradient echo images, using a positive
contrast method (GRASP), whereas no enhancement was
observed for control nontargeted LUSPIOs and larger
(~40 nm) LSPIOs. Coating the particles with lipids
prevented nonspecific uptake by macrophages, leading to
higher in vivo specificity for ox-LDL.
Endothelial Cells
Inflammation leads to increased expression of cell adhesion
molecules like ICAM-1, VCAM-1, and P-selectin by
endothelial cells via the inflammatory mediators IL-1 and
TNF-α. VCAM-1 expression is also induced by oxidized
low-density lipoproteins, which accumulate in the plaque
during atherogenesis. VCAM-1 is bound by very late
antigen-4 (VLA-4) on the cell surface of leukocytes
mediating their extravasation. McAteer et al. [8] designed
microparticles (diameter ~4.5 μm) of iron oxide conjugated
with antibodies directed against VCAM-1. In vitro, the
binding capacity of these microparticles to TNF-α–stimu-
lated mouse endothelial cells was demonstrated [8]. In vivo,
the VCAM-1–targeted microparticles were used to image
inflammatory changes to peritubular capillaries in murine
kidneys after ischemia reperfusion injury [9]. A cross-
linked iron oxide (CLIO) nanoparticle was applied to target
VCAM-1 expression by dysfunctional aortic endothelium
of cholesterol-fed apoE–/– mice [10, 11]. The CLIOs were
also equipped with a fluorescent moiety for fluorescence
imaging and VCAM-1 targeting was achieved by conjuga-
tion of a peptide sequence with homology to the a-chain of
VLA-4.
As a response to the upregulation of inflammatory
mediators, endothelial cells express P-selectin, which
interacts with P-selectin glycoprotein ligand-1. This inter-
action involves some basic amino acids of P-selectin and
sulfate residues carried by PSGL-1. The latter interaction
was exploited to target P-selectin in plaques of apoE–/–
mice with a slow-clearing blood-pool agent functionalized
with sulfate groups [12]. Application of this P-selectin–
targeted agent led to specific plaque enhancement between
10 and 30 min after intravenous injection. Ex vivo
fluorescence microscopy confirmed specific binding of the
agent to P-selectin.
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Neovascularization
The formation of neoangiogenic vessels has been associat-
ed with the hypoxic conditions in the thickened intimal
layer (>500 μm) [13]. Recent observations, however,
suggest that neovascularization may promote plaque in-
flammation and progression already at an early stage of
plaque formation by facilitating extravasation of inflamma-
tory cells [14]. Rapid carotid atherosclerotic plaque growth
has also been related to intraplaque hemorrhage of the
fragile neovasculature [15].
Dynamic contrast enhancement (DCE) MRI, a technique
well known for its ability to evaluate tumor vascularity,
recently finds new application in the assessment of human
plaque neovascularization [16]. DCE-MRI uses serial MRI
acquisitions with high temporal resolution before and
following the injection of a low-molecular-weight Gd-
containing contrast agent. DCE–MRI has demonstrated the
ability to differentiate fibrous tissue (enhancement ~80%)
from lipid core (enhancement ~30%) by virtue of the
neovessel density in fibrous tissue [16]. Appropriate
modeling of the signal intensity time course in the plaque
provides information on contrast agent plaque uptake
kinetics and estimations of the amount of neovasculariza-
tion and vessel permeability [17].
The above-described targeted approaches with Gd-based
contrast agents require high payloads of Gd accumulating at
the site of interest to generate sufficient contrast in the MR
images. Gadofluorine M (Bayer Schering Pharma AG) is an
amphiphile with perfluorinated side chains, which forms
micelles with a diameter of 5 to 6 nm in watery solution.
Gadofluorine M micelles accumulate in high concentrations
in atherosclerotic plaque, delivering an amount of Gd
which results in a high contrast-to-background ratio in T1-
weighted MRI [18]. Accumulation of micelles in the plaque
was attributed to enhanced vessel-wall permeability and
affinity of Gadofluorine M for plaque lipids [18]. Addi-
tionally, affinity of Gadofluorine M for extracellular matrix
proteins was observed [19]. Recently, Gadofluorine M
uptake in the balloon-injured aorta of New Zealand white
rabbits has been found to correlate with plaque neovessel
and macrophage density [20]. Histological evaluation
showed that plaque neovessels, lipid-rich regions, and
Gadofluorine M co-localized.
Also targeted approaches were used for the molecular
MR imaging of plaque neovascularization. Targeting of
endothelial receptors indicative for neovascularization has
the distinct advantage that the contrast agent need not enter
the plaque itself, which allows for the use of large, very
potent, nanoparticulate MR contrast agents. For example,
Gd-containing perfluorocarbon emulsion nanoparticles with
a size of about 250 nm were used to target plaque
neovascularization [21]. It was demonstrated that an
increased vasa vasorum density characterizes advanced
atherosclerotic plaque.
The rat with a mutation in the leptin receptor is a model
for metabolic syndrome, resulting in abdominal obesity,
atherosclerosis, and myocardial lesions. Neovascularization
in plaques in the aorta of these rats was imaged using a Gd-
containing perfluorocarbon emulsion targeted toward the
αvβ3 integrin expressed on the vascular endothelium [21].
Additionally, the influence on plaque neovascularization of
treatment with the anorectic and hypolipidemic drug
benfluorex was investigated. Treated animals displayed an
overall lower and patchy plaque enhancement in compar-
ison to non-treated ones, indicative for a decreased
angiogenic vessel density in the plaque. This study
demonstrated successful application of these molecular
MRI approaches to study neovascularization in atheroscle-
rosis and changes therein upon treatment. The same αvβ3-
targeted nanoparticles were used to study treatment with
angiogenic L-arginine in a rabbit femoral artery ligation
model [22]. The achieved results in these diverse studies
warn of one-sided interpretation of MR imaging results in
atherosclerosis using αvβ3-targeted nanoparticles. Molecu-
lar MRI of neovascularization with these nanoparticles may
not discriminate between adverse plaque neovessels and
beneficial sprouting of collaterals.
Macrophages
Using molecular MRI, probably the most extensively studied
plaque components are the macrophages. Previously, dextran-
coated USPIOs (diameter 18–30 nm) were applied to
discriminate healthy lymph nodes from ones that contain
metastatic tumor tissue [23]. One of these MRI studies
showed upon careful analysis not only ingestion of these
USPIOs by macrophages in the lymph node but also by
aortic plaque macrophages [24]. Nevertheless, accumulation
of iron oxides in lymph nodes may complicate their
application to detect macrophages in atherosclerotic plaque,
since lymph nodes often develop in close proximity to the
inflamed plaque lesion. We have shown that differentiation
between perivascular lymph nodes and aortic wall in
atherosclerotic mouse models may be difficult using USPIOs
(diameter 18–30 nm) and successful visualization will
depend on resolution and the imaging sequence (fast spin
echo instead of gradient echo) [25]. Recently, it was shown
that the GRASP imaging technique, producing positive
contrast with SPIOs, was capable of differentiating the
perivascular lymph nodes from the vessel wall [7].
USPIOs have also found their way to the clinic for
atherosclerotic plaque imaging. In a study by Kooi et al.
[26], patients who were scheduled for carotid endarterectomy
were first scanned byMRI and next injected with USPIOs. At
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24 h after injection, T2*-weighted images of the carotid artery
wall showed decreased signal intensity, which normalized at
72 h after injection [26]. Following surgical removal of the
lesioned carotid artery, 75% of ruptured and rupture-prone
plaques were positive for USPIOs on histological analysis
compared to 7% of stable plaques [26]. Investigation of the
contralateral side in patients with symptomatic carotid
stenosis demonstrated uptake of USPIOs in 95% of plaques,
despite a mean stenosis of only 46% [27]. This result
emphasizes the truly systemic nature of atherosclerosis. Also
the difference in effect between aggressive and mild lipid-
lowering therapy on atherosclerotic plaque macrophages of
patients was successfully investigated, using USPIO-based
detection by MRI [28].
Specific targeting of macrophages in murine plaque has
been achieved with paramagnetic Gd–containing micelles
directed toward the membrane-bound macrophage scavenger
receptor-A (MSR-A). Plaques in the aortic wall of apoE–/–
mice displayed a 79% increase in signal intensity upon
injection of the MSR-A–targeted micelles, whereas control
micelles resulted in 34% signal increase [29]. MSR-A
together with MSR-B is responsible for 75%–90% of ox–
LDL uptake by macrophages. The latter has been targeted
with 125-nm–diameter lipid–based nanoparticles ex vivo in
dissected human aortas containing atherosclerotic lesions
[30]. However, in vivo application of MSR-B–targeted
nanoparticles has not been demonstrated yet and confound-
ing factors, such as binding by Kuppfer cells in the liver,
have still to be addressed.
Ox-LDL binds to the ox-LDL receptor LOX-1 and
induces apoptosis, expression of adhesion molecules, and
release of MMPs [1, 31]. Injection of paramagnetic
liposomes conjugated with anti–LOX–1 antibodies in
LDL–R–/– mice induced specific MRI–signal enhancement
in plaques in the aorta. Enhancement was neither observed
in double knockout LDL–R–/– LOX–1–/– mice nor in
LDL–R–/– mice injected with nonspecific IgG-conjugated
liposomes [31]. Histological analyses revealed that most
LOX-1 co-localized with macrophages, apoptotic cells, and
MMP-9 and only a small proportion with proliferated
smooth muscle cells.
Distinct disadvantages of the targeted approach with
antibodies are the difficulty in handling and preparation,
costs of antibodies, immunogenicity, and possible steric
hindrance by PEG reducing the specific interactions. An
alternative approach is the use of specific targeting moieties
of non-antibody origin. An example is the use of Gd–
containing liposomes with phosphatidylserine (PS) incor-
porated in the lipid membrane. PS is expressed on apoptotic
cells in the plaque and is specifically recognized by
macrophages. Using that same mechanism, PS–containing
liposomes are specifically phagocytosed by macrophages in
the plaque. In vitro PS-containing liposomes showed
specificity for RAW cells (murine macrophages), and signif-
icant enhancement of plaques in the aortic wall of apoE–/-
mice was observed in vivo up to 4 h after injection [32].
In another study, plaque macrophages were targeted
using a potent synthetic agonist (HU–308) of the peripheral
cannabinoid receptor (CB2-R) [33]. CB2-R is expressed by
T-lymphocytes and macrophages in advanced murine and
human atherosclerotic plaque and is believed to dampen the
inflammatory process in advanced plaques [34]. HU-308,
which has a 7–carbon tail and a hydrophilic head group,
was mixed with Gd-containing and PEG-ylated lipids to
form MRI–visible micelles [33]. In vivo plaque enhance-
ment in the aortas of double knockout apoE–/- eNOS–/-
mice was observed from 36 to 48 h after injection of the
CB2–R–targeted micelles using black-blood T1-weighted
inversion recovery fast spin echo MRI [35].
HDL-like nanoparticles functionalized with an apoE-
derived lipopeptide were used to target macrophages in the
atherosclerotic lesions in the aorta of apoE–/- mice [36].
Various versions of HDL-mimicking nanoparticles have
been designed for plaque imaging [37]. An attractive
property of such particles is that HDL is of endogenous
nature, small, and plays a key role in plaque etiology.
Among others, HDL enables reverse cholesterol transport
from the plaque, has anti-atherothrombotic properties, and
reduces oxidation and plaque inflammation. These MRI–
visible nanoparticles might be useful to study the role of
HDL in plaque progression [38].
Iron oxides with a lipid coating and conjugated with
hyaluronic acid (HA), which targets the CD44 receptor on
activated macrophages, were employed to study plaque
inflammation as well [39]. Cellular uptake of these CD44-
targeted iron oxides was demonstrated in vitro for activated
THP–1 macrophages. Prussian blue stainings for iron
revealed that the nanoparticles were only transiently present
in the cells, which is beneficial in view of possible toxicity
issues. In vivo application of these macrophage-targeted
iron oxides has still to be demonstrated.
Apart from direct targeting of macrophages, one can also
address the presence of extracellular enzymes or proteins in
the plaque associated with inflammation. Plaque rupture has
been attributed to increased activity of matrix metalloprotei-
nases (MMPs) produced by SMCs and macrophages [40]. In
vivo MR imaging of plaque MMP expression has been
demonstrated using a small peptide with affinity for MMPs
covalently bound to Gd-DOTA [41]. Specific inhibitors of
MMP–2 and MMP–9 may be used for improved targeting of
MMPs in the plaque. A protein that has been linked to
adverse cardiovascular events in patients after carotid
endarterectomy surgery is neutrophil gelatinase-associated
lipocalin–2 (NGAL) [42]. First discovered in human
neutrophils, NGAL is produced and released particularly by
macrophages. It is able to form a stable, biologically active
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complex with MMP-9, preventing its degradation and
thereby prolonging MMP-9 activity. Additionally, it
mediates inflammatory activity through binding to
formyl-methionyl-leucyl-phenylalanine (fMLP; a chemotactic
peptide), leukotriene B4, and platelet-activating factor. As
summarized in Fig. 1, the mouse homologue of NGAL, 24p3,
was successfully imaged with 24p3–targetedmicelles in severe
atherosclerotic plaques of the double knockout apoE–/–
eNOS–/– mouse [42]. Histology proved that micelles co-
localized with 24p3 and partially with macrophages.
On the one hand, targeting of extracellular-located
molecules such as MMPs and NGAL has the advantage
that the target is readily available. On the other hand, it may
carry the drawback that the contrast agent is easily washed
out from the plaque into the blood. Nevertheless, imaging
of excreted proteins could provide important insights in the
inflammatory state of the plaque. For example, peroxidase-
based hematologic profiling has been shown to predict
adverse cardiac events during a follow-up of 1 year [43]. In
order to prevent washout of the agent, Ronald and
coworkers [44••] have designed an activatable (smart) Gd-
containing probe for imaging of myeloperoxidase, an
enzyme released by macrophages that is responsible for
oxidation of LDL via the formation of reactive oxygen
species. Activation of the probe by myeloperoxidase leads
to polymerization, increasing its size and preventing
washout from the target region—hence providing an
indirect readout of enzyme activity. As summarized in
Fig. 2, with this probe increased myeloperoxidase activity
was imaged in plaques in the aorta of rabbits [44••].
Apoptotic Cells
One of the characteristics of apoptotic cells is that PS,
which is only found in the inner leaflet of the viable cell
membrane, becomes expressed on the outer leaflet of the
cell. The expression of PS can be used for MR imaging of
apoptosis by using the protein annexin A5 as a targeting
ligand. Annexin A5 binds specifically to PS in the presence
of calcium. Gd–containing micelles, conjugated with
annexin A5, were employed to study apoptosis in athero-
sclerotic plaques in the aorta of apoE–/– mice. Twenty-four
hours after intravenous injection, enhancement of the
plaque was observed on T1–weighted MRI, which was
slightly, but significantly, higher than for control nonspe-
cific micelles [45]. In another study, a PS–specific peptide,
which was identified by phage display, was conjugated to
Gd–DTPA. Thirty minutes after intravenous injection, a
specific enhancement of plaques in the aorta of apoE–/–
mice was observed [46]. The use of small peptides has
certain advantages above proteins or antibodies in terms of
reduced immunogenicity, as well as a cheaper and easier
production process.
Fig. 1 Magnetic resonance (MR) images and histological stainings of
murine atherosclerotic plaque after intravenous injection of NGAL/
24p3–targeted micelles. Pre-injection and post-injection (0, 24, and
72 h) MR images of aortic wall in apoE–/–/eNOS–/– mice injected with
control (a–c) and NGAL/24p3-targeted (e–g) micelles. Histology of
the mouse aorta at 72 h after injection revealed no staining of micelles
for injections with control micelles (d) and extensive red staining for
injections with NGAL/24p3-targeted micelles (h). The post–injection
MR images show plaque enhancement and also enhancement of a
lymph node, which was removed during harvesting of the aorta. H:
scale bar = 100 μm (original magnification: 100×). LN, lymph node;
P, plaque
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Activated Platelets and Thrombus
Activated platelets play a crucial role in the formation of
micro-thrombi, which eventually may accumulate in an
acute cardiovascular event. Therefore, early recognition of
frequently occurring minor atherothrombosis has impor-
tant prognostic value. Ultra-small particles of iron oxide
have been conjugated with cyclic arginine–glycine–
aspartic acid (RGD) peptides specific for the αIIβ3
integrin among others, which is expressed on activated
platelets [47]. Unfortunately, the resolution, which was
achieved with RGD-USPIO-enhanced MRI, was too low
to detect thrombus in vivo. Recently, single-chain anti-
bodies (scFv) have been successfully conjugated to iron
nanoparticles using the Staphylococcus aureus sortase A
enzyme for molecular imaging in cardiovascular disease.
Binding of scFv-conjugated nanoparticles to activated
platelets was demonstrated in vivo in mouse carotid
arteries [48]. Another single-chain antibody aimed to
target ligand-induced binding sites on activated glyco-
protein IIb/IIIa was conjugated to microparticles of iron
oxide (diameter 1 μm) [49]. Ferric chloride-induced
thrombi were imaged repeatedly in mice after injection
of this contrast agent with a significant decrease of signal
intensity at 36 min after injection [49]. After thrombolysis
the signal increased again, indicating that this approach
enables the evaluation of the efficacy of thrombolytic
therapy.
Various products of the coagulation cascade may serve as
targets for molecular MRI. Fibrin–targeted small-molecule
peptides conjugated to Gd-DTPA have been applied success-
fully in patients to image thrombus [50••]. Fibrin-specific Gd-
perfluorocarbon nanoparticles were also applied for MR
imaging of thrombus [51]. The perfluorocarbon nano-
particles can be used for T1-weighted proton MRI as well
as for 19F hot–spot MR imaging. Finally, also contrast agents
based on the chemical exchange saturation transfer (CEST)
mechanism [52] have been employed for imaging of fibrin.
Proof-of-concept CEST imaging of fibrin was provided in
vitro for fibrin clots, using a fibrin-specific perfluorocarbon
nanoparticle containing a paraCEST compound [53•]. The
CEST agents are potentially attractive for in vivo use,
because contrast can be switched on and off by selective
RF pulse saturation, avoiding the need for pre-injection and
post–injection imaging which is for clinical application and
not attractive from a logistical point of view.
Limitations
As described above, MRI is capable of providing detailed
cellular and molecular imaging information, which com-
bined with the wealth of anatomical and functional MRI
readouts, makes MR imaging of atherosclerosis a very
powerful asset to study plaque vulnerability, progression,
and to evaluate effects of treatment. A potential limitation
Fig. 2 Magnetic resonance (MR) images and histological staining of
rabbit atherosclerotic plaque after injection of an activatable MPO
sensor. Imaging of aortas of cholesterol-fed rabbits before and 2 h
after injection of DTPA-Gd (a, d), before and 2 h after injection of bis-
tyr-DTPA-Gd (b, e), which is a non-activatable analog of MPO-Gd,
and before and 2 h after injection of MPO-Gd (c, f). Histology of the
rabbit aorta (g) after injection of MPO-Gd revealed focal MPO
presence in the plaque and confirmed the MR findings. (From Ronald
et al. [44••]; with permission)
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of MRI, however, is the limited sensitivity of the technique
in the detection of low concentrations of targeted contrast
agent. Although single-cell detection with the use of iron
oxides has been reported, in general, much higher doses are
needed as compared to, for example, the nuclear imaging
techniques [2]. This complicates rapid approval of MR
contrast agents and its carriers for human application by the
FDA (USA) and EMEA (Europe), because of the concerns
about retention in the body and toxicity. Issues are, amongst
others, the unknown metabolic fate of the carrier material in
the body, transmetallation of Gd3+ with native metal-ions in
the body [4], and worries about Gd-induced nephrogenic
systemic fibrosis [6].
The use of frequency-selective paraCEST agents or
perfluorocarbon nanoparticles permits imaging of vari-
ous target species simultaneously. Although in vitro
proof-of-principle has been provided, in vivo application
has been limited so far. Problems for paraCEST agents
are related to low sensitivity and susceptibility artifacts,
whereas 19F imaging also suffers from relatively low
sensitivity. Concerning clinical translation, the iron oxides
are most promising, since they enable the most sensitive
detection while toxicity is low. The larger iron oxides
provide sensitive hypointense contrast on T2-weighted
images, whereas small iron oxides (~5 nm) can also be
used for T1–weighted imaging with hyperintense contrast
[54•].
Conclusions
As reviewed in this paper, in recent years a number of MRI
strategies to image inflammation in atherosclerotic plaques
were successfully developed. Proof-of-concept clinical
application was already established for imaging of macro-
phages using non-targeted iron oxides. Future studies will
have to clarify whether the targeted contrast agents will
have diagnostic or prognostic added value in the evaluation
of atherosclerotic plaque inflammation in humans. Promis-
ing new developments include activatable contrast agents,
which are able to report on enzyme activity, as well as the
use of MRI-visible endogenous nanoparticles, such as HDL
and LDL, for imaging of atherosclerosis and plaque
inflammation.
Disclosure No potential conflicts of interest relevant to this article
were reported.
Open Access This article is distributed under the terms of the Creative
Commons Attribution Noncommercial License which permits any
noncommercial use, distribution, and reproduction in any medium,
provided the original author(s) and source are credited.
References
Papers of particular interest, published recently, have been
highlighted as:
• Of importance
•• Of major importance
1. Ross R. Atherosclerosis is an inflammatory disease. Am Heart J.
1999;138:S419–20.
2. Leuschner F, Nahrendorf M. Molecular imaging of coronary
atherosclerosis and myocardial infarction: considerations for the
bench and perspectives for the clinic. Circ Res. 2011;108:593–606.
3. Briley-Saebo KC, Shaw PX, Mulder WJ, et al. Targeted molecular
probes for imaging atherosclerotic lesions with magnetic reso-
nance using antibodies that recognize oxidation-specific epitopes.
Circulation. 2008;117:3206–15.
4. Hak S, Sanders HM, Agrawal P, et al. A high relaxivity Gd(III)
DOTA-DSPE-based liposomal contrast agent for magnetic reso-
nance imaging. Eur J Pharm Biopharm. 2009;72:397–404.
5. Ide M, Kuwamura M, Kotani T, et al. Effects of gadolinium
chloride (GdCl(3)) on the appearance of macrophage populations
and fibrogenesis in thioacetamide-induced rat hepatic lesions. J
Comp Pathol. 2005;133:92–102.
6. Pedersen M. Safety update on the possible causal relationship
between gadolinium-containing MRI agents and nephrogenic
systemic fibrosis. J Magn Reson Imaging. 2007;25:881–3.
7. Briley-Saebo KC, Cho YS, Shaw PX, et al. Targeted iron oxide
particles for in vivo magnetic resonance detection of atheroscle-
rotic lesions with antibodies directed to oxidation-specific
epitopes. J Am Coll Cardiol. 2011;57:337–47.
8. McAteer MA, Akhtar AM, von Zur MC, et al. An approach to
molecular imaging of atherosclerosis, thrombosis, and vascular
inflammation using microparticles of iron oxide. Atherosclerosis.
2010;209:18–27.
9. Akhtar AM, Schneider JE, Chapman SJ, et al. In vivo quantifi-
cation of VCAM-1 expression in renal ischemia reperfusion injury
using non-invasive magnetic resonance molecular imaging. PLoS
One. 2010;5:e12800.
10. Kelly KA, Allport JR, Tsourkas A, et al. Detection of vascular
adhesion molecule-1 expression using a novel multimodal nano-
particle. Circ Res. 2005;96:327–36.
11. Nahrendorf M, Jaffer FA, Kelly KA, et al. Noninvasive vascular
cell adhesion molecule-1 imaging identifies inflammatory activa-
tion of cells in atherosclerosis. Circulation. 2006;114:1504–11.
12. Alsaid H, De SG, Bourdillon MC, et al. Biomimetic MRI contrast
agent for imaging of inflammation in atherosclerotic plaque of
ApoE–/– mice: a pilot study. Invest Radiol. 2009;44:151–8.
13. Sluimer JC, Daemen MJ. Novel concepts in atherogenesis:
angiogenesis and hypoxia in atherosclerosis. J Pathol. 2009;218:7–
29.
14. Dunmore BJ, McCarthy MJ, Naylor AR, et al. Carotid plaque
instability and ischemic symptoms are linked to immaturity of
microvessels within plaques. J Vasc Surg. 2007;45:155–9.
15. Takaya N, Yuan C, Chu B, et al. Presence of intraplaque
hemorrhage stimulates progression of carotid atherosclerotic
plaques: a high-resolution magnetic resonance imaging study.
Circulation. 2005;111:2768–75.
16. Yuan C, Kerwin WS, Ferguson MS, et al. Contrast-enhanced high
resolution MRI for atherosclerotic carotid artery tissue character-
ization. J Magn Reson Imaging. 2002;15:62–7.
17. Calcagno C, Mani V, Ramachandran S, et al. Dynamic
contrast enhanced (DCE) magnetic resonance imaging (MRI)
of atherosclerotic plaque angiogenesis. Angiogenesis. 2010;13:87–
99.
66 Curr Cardiovasc Imaging Rep (2012) 5:60–68
18. Barkhausen J, Ebert W, Heyer C, et al. Detection of atheroscle-
rotic plaque with Gadofluorine-enhanced magnetic resonance
imaging. Circulation. 2003;108:605–9.
19. Meding J, Urich M, Licha K, et al. Magnetic resonance imaging
of atherosclerosis by targeting extracellular matrix deposition with
gadofluorine M. Contrast Media Mol Imaging. 2007;2:120–9.
20. Sirol M, Moreno PR, Purushothaman KR, et al. Increased
neovascularization in advanced lipid-rich atherosclerotic
lesions detected by gadofluorine-M-enhanced MRI: implica-
tions for plaque vulnerability. Circ Cardiovasc Imaging.
2009;2:391–6.
21. Cai K, Caruthers SD, Huang W, et al. MR molecular imaging of
aortic angiogenesis. JACC Cardiovasc Imaging. 2010;3:824–32.
22. Winter PM, Caruthers SD, Allen JS, et al. Molecular imaging of
angiogenic therapy in peripheral vascular disease with
alphanubeta3-integrin-targeted nanoparticles. Magn Reson Med.
2010;64:369–76.
23. Schmitz SA. Iron-oxide-enhanced MR imaging of inflammatory
atherosclerotic lesions: overview of experimental and initial
clinical results. Rofo. 2003;175:469–76.
24. Schmitz SA, Taupitz M, Wagner S, et al. Magnetic resonance
imaging of atherosclerotic plaques using superparamagnetic iron
oxide particles. J Magn Reson Imaging. 2001;14:355–61.
25. Te Boekhorst BC, Bovens SM, Nederhoff MG, et al. Negative
MR contrast caused by USPIO uptake in lymph nodes may lead to
false positive observations with in vivo visualization of murine
atherosclerotic plaque. Atherosclerosis. 2010;210:122–9.
26. Kooi ME, Cappendijk VC, Cleutjens KB, et al. Accumulation of
ultrasmall superparamagnetic particles of iron oxide in human
atherosclerotic plaques can be detected by in vivo magnetic
resonance imaging. Circulation. 2003;107:2453–8.
27. Tang T, Howarth SP, Miller SR, et al. Assessment of inflammatory
burden contralateral to the symptomatic carotid stenosis using
high-resolution ultrasmall, superparamagnetic iron oxide-
enhanced MRI. Stroke. 2006;37:2266–70.
28. Tang TY, Howarth SP, Miller SR, et al. The ATHEROMA
(atorvastatin therapy: effects on reduction of macrophage activity)
study. Evaluation using ultrasmall superparamagnetic iron oxide-
enhanced magnetic resonance imaging in carotid disease. J Am
Coll Cardiol. 2009;53:2039–50.
29. Amirbekian V, Lipinski MJ, Briley-Saebo KC, et al. Detecting and
assessing macrophages in vivo to evaluate atherosclerosis non-
invasively using molecular MRI. Proc Natl Acad Sci U S A.
2007;104:961–6.
30. Lipinski MJ, Frias JC, Amirbekian V, et al. Macrophage-specific
lipid-based nanoparticles improve cardiac magnetic resonance
detection and characterization of human atherosclerosis. JACC
Cardiovasc Imaging. 2009;2:637–47.
31. Li D, Patel AR, Klibanov AL, et al. Molecular imaging of
atherosclerotic plaques targeted to oxidized LDL receptor LOX-1
by SPECT/CT and magnetic resonance. Circ Cardiovasc Imaging.
2010;3:464–72.
32. Maiseyeu A, Mihai G, Kampfrath T, et al. Gadolinium-containing
phosphatidylserine liposomes for molecular imaging of athero-
sclerosis. J Lipid Res. 2009;50:2157–63.
33. Te Boekhorst BC, Bovens SM, Rodrigues-Feo J, et al. Characteriza-
tion and in vitro and in vivo testing of CB2-receptor- and NGAL-
targeted paramagnetic micelles for molecular MRI of vulnerable
atherosclerotic plaque. Mol Imaging Biol. 2010;12:635–51.
34. Steffens S, Veillard NR, Arnaud C, et al. Low dose oral
cannabinoid therapy reduces progression of atherosclerosis in
mice. Nature. 2005;434:782–6.
35. Te Boekhorst BC, Bovens SM, van de Kolk CW, et al. The time
window of MRI of murine atherosclerotic plaques after adminis-
tration of CB2 receptor targeted micelles: inter-scan variability
and relation between plaque signal intensity increase and
gadolinium content of inversion recovery prepared versus non-
prepared fast spin echo. NMR Biomed. 2010;23:939–51.
36. Chen W, Vucic E, Leupold E, et al. Incorporation of an apoE-
derived lipopeptide in high-density lipoprotein MRI contrast
agents for enhanced imaging of macrophages in atherosclerosis.
Contrast Media Mol Imaging. 2008;3:233–42.
37. Cormode DP, Briley-Saebo KC, Mulder WJ, et al. An ApoA-I
mimetic peptide high-density-lipoprotein-based MRI contrast
agent for atherosclerotic plaque composition detection. Small.
2008;4:1437–44.
38. Skajaa T, Cormode DP, Falk E, et al. High-density lipoprotein-
based contrast agents for multimodal imaging of atherosclerosis.
Arterioscler Thromb Vasc Biol. 2010;30:169–76.
39. Kamat M, El-Boubbou K, Zhu DC, et al. Hyaluronic acid
immobilized magnetic nanoparticles for active targeting and
imaging of macrophages. Bioconjug Chem. 2010;21:2128–35.
40. Schafers M, Schober O, Hermann S. Matrix-metalloproteinases as
imaging targets for inflammatory activity in atherosclerotic
plaques. J Nucl Med. 2010;51:663–6.
41. Lancelot E, Amirbekian V, Brigger I, et al. Evaluation of
matrix metalloproteinases in atherosclerosis using a novel
noninvasive imaging approach. Arterioscler Thromb Vasc Biol.
2008;28:425–32.
42. Te Boekhorst BC, Bovens SM, Hellings WE, et al. Molecular
MRI of murine atherosclerotic plaque targeting NGAL: a protein
associated with unstable human plaque characteristics. Cardiovasc
Res. 2011;89:680–8.
43. Brennan ML, Reddy A, Tang WH, et al. Comprehensive
peroxidase-based hematologic profiling for the prediction of
1-year myocardial infarction and death. Circulation. 2010;
122:70–9.
44. •• Ronald JA, Chen JW, Chen Y, et al. Enzyme-sensitive magnetic
resonance imaging targeting myeloperoxidase identifies active
inflammation in experimental rabbit atherosclerotic plaques.
Circulation. 2009;120:592–9. In vivo potential of activatable
contrast agents for visualization of enzyme activity in plaques
with MRI.
45. van Tilborg GA, Vucic E, Strijkers GJ, et al. Annexin A5-
functionalized bimodal nanoparticles for MRI and fluorescence
imaging of atherosclerotic plaques. Bioconjug Chem.
2010;21:1794–803.
46. Burtea C, Laurent S, Lancelot E, et al. Peptidic targeting of
phosphatidylserine for the MRI detection of apoptosis in
atherosclerotic plaques. Mol Pharm. 2009;6:1903–19.
47. Johansson LO, Bjornerud A, Ahlstrom HK, et al. A targeted contrast
agent for magnetic resonance imaging of thrombus: implications of
spatial resolution. J Magn Reson Imaging. 2001;13:615–8.
48. Ta HT, Prabhu S, Leitner E, et al. Enzymatic single-chain
antibody tagging: a universal approach to targeted molecular
imaging and cell homing in cardiovascular disease. Circ Res.
2011, Epub ahead of print.
49. Von zur Muhlen C, Von Elverfeldt D, Moeller JA, et al. Magnetic
resonance imaging contrast agent targeted toward activated
platelets allows in vivo detection of thrombosis and monitoring
of thrombolysis. Circulation. 2008;118:258–67.
50. •• Spuentrup E, Botnar RM, Wiethoff AJ, et al. MR imaging of
thrombi using EP-2104R, a fibrin-specific contrast agent: initial
results in patients. Eur Radiol. 2008;18:1995–2005. In vivo
clinical applicability of small gadolinium-based fibrin-targeted
contrast agent.
51. Morawski AM, Winter PM, Yu X, et al. Quantitative “magnetic
resonance immunohistochemistry” with ligand-targeted (19)F
nanoparticles. Magn Reson Med. 2004;52:1255–62.
52. Ward KM, Aletras AH, Balaban RS. A new class of contrast
agents for MRI based on proton chemical exchange dependent
saturation transfer (CEST). J Magn Reson. 2000;143:79–87.
Curr Cardiovasc Imaging Rep (2012) 5:60–68 67
53. • Winter PM, Cai K, Chen J, et al. Targeted PARACEST
nanoparticle contrast agent for the detection of fibrin. Magn
Reson Med. 2006;56:1384–8. An example of fibrin-targeting with
a paraCEST contrast agent with possible transfer to the clinic.
54. • Taboada E, Rodriguez E, Roig A, et al. Relaxometric and magnetic
characterization of ultrasmall iron oxide nanoparticles with high
magnetization. Evaluation as potential T1 magnetic resonance
imaging contrast agents for molecular imaging. Langmuir.
2007;23:4583–8. Description of the T1 contrast properties of iron
oxide–based nanoparticles, which have less toxicity issues when
compared to gadolinium-based nanoparticles. Positive contrast
caused by shortened T1 is not masked by susceptibility artifacts and
area of contrast uptake will not be overestimated as is the case with
T2* contrast.
68 Curr Cardiovasc Imaging Rep (2012) 5:60–68
